STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) director Dan Gold reported several open‑market sales of the company’s Common Shares on 11/19/2025. Indirectly through QVT Financial Investment Cayman Ltd., he sold 850,000 shares at $20.25, 150,000 shares at $20.20, 125,000 shares at $20.16, and 175,000 shares at $20.24, all coded as sales. Following these transactions, 18,047,727 Common Shares were beneficially owned indirectly, reported as held by QVT Financial Investment Cayman Ltd. The filing notes that Gold is one of three directors of QVT Financial Investment Cayman Ltd., shares voting and investment control over these shares, and disclaims beneficial ownership beyond his pecuniary interest.

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gold Daniel Allen

(Last) (First) (Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY

(Street)
LONDON X0 SW1H 0DB

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
11/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 11/19/2025 S 850,000 D $20.25 18,497,727 I(1) Held by QVT Financial Investment Cayman Ltd.
Common Shares 11/19/2025 S 150,000 D $20.2 18,347,727 I(1) Held by QVT Financial Investment Cayman Ltd.
Common Shares 11/19/2025 S 125,000 D $20.16 18,222,727 I(1) Held by QVT Financial Investment Cayman Ltd.
Common Shares 11/19/2025 S 175,000 D $20.24 18,047,727 I(1) Held by QVT Financial Investment Cayman Ltd.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.
/s/ Dan Gold 11/21/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ROIV director Dan Gold report on this Form 4?

Dan Gold reported multiple open‑market sales of Roivant Sciences Ltd. (ROIV) Common Shares on 11/19/2025, all coded as sales of indirectly held shares.

How many Roivant (ROIV) shares were sold in the reported transactions?

The reported sales were in blocks of 850,000, 150,000, 125,000, and 175,000 Common Shares, each recorded as a separate transaction on 11/19/2025.

What prices were received for the Roivant (ROIV) share sales?

The Common Shares were sold at prices of $20.25, $20.20, $20.16, and $20.24 per share in the transactions reported for 11/19/2025.

How many Roivant (ROIV) shares does Dan Gold report beneficially owning after these sales?

After the reported transactions, the filing shows 18,047,727 Common Shares beneficially owned indirectly, held by QVT Financial Investment Cayman Ltd.

How are Dan Gold’s Roivant (ROIV) holdings structured?

The holdings are reported as indirect (I), held by QVT Financial Investment Cayman Ltd., where Dan Gold is one of three directors sharing voting and investment control over the Common Shares.

Does Dan Gold claim full beneficial ownership of the reported Roivant shares?

No. The filing states that Dan Gold disclaims beneficial ownership of the securities except to the extent of his pecuniary interest, despite reporting them as indirectly held.

Roivant Sciences

NASDAQ:ROIV

ROIV Rankings

ROIV Latest News

ROIV Latest SEC Filings

ROIV Stock Data

14.10B
455.99M
26.13%
76.8%
5.72%
Biotechnology
Pharmaceutical Preparations
Link
United Kingdom
LONDON